According to FutureWise analysis the market for biomarker technologies is expected to reach US$ 122.5 billion by 2031 at a CAGR of 14.5%. Biomarker technologies focus on the identification, measurement, and application of biomarkers—biological indicators that provide quantifiable evidence of physiological or pathological processes within the body. These biomarkers, which can include...

According to FutureWise analysis the market for biologics safety testing in 2023 was US$ 4.08 billion, and is expected to reach US$ 11.18 billion by 2031 at a CAGR of 13.4%. Biologics are a category of therapeutic products sourced from living organisms. This includes a variety of treatments such as proteins, monoclonal antibodies, vaccines, as well as cell and gene therapies. Unlike...

According to FutureWise analysis the market for biologics outsourcing in 2023 is US$ 95.61 billion, and is expected to reach US$ 382.43 billion by 2031 at a CAGR of 18.92%. Biologics outsourcing refers to the practice of entrusting the development, manufacturing, and testing of biologic drugs—complex molecules sourced from living organisms, including monoclonal antibodies, vaccines, and...

According to FutureWise analysis the market for biologics contract manufacturing demand in 2023 was US$ 17.41 billion, and is expected to reach US$ 39.31 billion by 2031 at a CAGR of 10.72%. Biologics contract manufacturing is a vital part of the biopharmaceutical industry, focusing on the outsourcing of the production of complex biologic drugs, including monoclonal antibodies, vaccines, and...

Biologics and biosimilars are pivotal components of contemporary medicine, significantly influencing the treatment landscape for complex diseases. Biologics are sophisticated therapeutic products derived from living organisms, such as proteins, antibodies, or cells, specifically engineered to target particular disease pathways with precision. Unlike traditional small-molecule drugs, which are...

According to FutureWise analysis the market for biologics contract development in 2023 was US$ 7.91 billion, and is expected to reach US$ 14.99 billion by 2031 at a CAGR of 8.30%. Biologics contract development involves the outsourcing of various processes related to the research, development, and optimization of biologics, which are complex therapeutic molecules derived from living organisms....

According to FutureWise analysis the market for biological imaging reagent in 2023 was US$ 20.51 billion, and is expected to reach US$ 40.03 billion by 2031 at a CAGR of 8.70%. Biological imaging reagents are specialized molecules or compounds used to visualize and study biological processes at the cellular, tissue, or organismal level. These reagents are critical tools in biomedical research,...

Biological derived devices, also known as bio-derived or bio-inspired devices, represent a significant advancement at the convergence of biology, engineering, and materials science. These innovative devices utilize biological systems or principles to create cutting-edge technological solutions. By incorporating living organisms, biological molecules, or biomimetic designs, they serve a variety...

According to FutureWise analysis the market for biological data visualization in 2023 was US$ 0.58 billion, and is expected to reach US$ 1.46 billion by 2031 at a CAGR of 12.2%. Biological data visualization is a crucial field that transforms complex biological datasets into clear visual representations, enabling researchers, scientists, and policymakers to interpret intricate patterns,...

According to FutureWise analysis the market for Biological And Chemical Indicators in 2023 was US$ 0.49 billion, and is expected to reach US$ 0.79 billion by 2031 at a CAGR of 6.10%. Biological and chemical indicators play a crucial role in environmental science, ecology, and sterilization processes, serving as reliable tools for assessing ecosystem health and ensuring sterility in essential...